CRBU (Caribou Biosciences) EPS (Basic) : $-1.65 (TTM As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Caribou Biosciences EPS (Basic)?

Caribou Biosciences's basic earnings per share (Basic EPS) for the three months ended in Dec. 2024 was $-0.39. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.65.

Caribou Biosciences's EPS (Diluted) for the three months ended in Dec. 2024 was $-0.39. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-1.65.

Caribou Biosciences's EPS without NRI for the three months ended in Dec. 2024 was $-0.39. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was -1.65.

During the past 3 years, the average EPS without NRI Growth Rate was 8.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was -9.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 6 years, Caribou Biosciences's highest 3-Year average EPS without NRI Growth Rate was 8.40% per year. The lowest was -21.60% per year. And the median was -4.30% per year.

Caribou Biosciences EPS (Basic) Historical Data

The historical data trend for Caribou Biosciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Caribou Biosciences EPS (Basic) Chart

Caribou Biosciences Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EPS (Basic)

Get a 7-Day Free Trial

-1.24

-2.11

-1.64

-1.38

-1.65

Caribou Biosciences Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EPS (Basic)	Get a 7-Day Free Trial															-0.40	-0.46	-0.42	-0.38	-0.39

Caribou Biosciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Caribou Biosciences's Basic EPS for the fiscal year that ended in Dec. 2024 is calculated as

Basic EPS (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-149.105	-	0)	/	90.318
	=	-1.65

Caribou Biosciences's Basic EPS for the quarter that ended in Dec. 2024 is calculated as

Basic EPS (Q: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-35.49	-	0)	/	91.167
	=	-0.39

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.65

Caribou Biosciences (NAS:CRBU) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Caribou Biosciences EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Caribou Biosciences's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Caribou Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Caribou Biosciences Inc (NAS:CRBU) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

2929 7th Street, Suite 105, Berkeley, CA, USA, 94710

Website

https://www.cariboubio.com

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.

Executives

Rachel E. Haurwitz	director, officer: See Remarks	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Ruhi Ahmad Khan	officer: Chief Business Officer	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Barbara G Mcclung	officer: See Remarks	CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Steven Kanner	officer: See Remarks	CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Syed Ali-aamir Rizvi	officer: Chief Medical Officer	C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Ryan Fischesser	officer: See Remarks	CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
David Lee Johnson	director	C/O GLOBAL BLOOD THERAPEUTICS, 171 OYSTER POINT BLVD, STE. 300, SAN FRANCISCO CA 94080
Dara Richardson-heron	director	C/O CARIBOU BIOSCIENCES, INC., 29, BERKELEY CA 94710
Ran Zheng	director	2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Nancy Whiting	director	2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Fmr Llc	10 percent owner, other: See Remark 1	245 SUMMER STREET, BOSTON MA 02210
Natalie Sacks	director	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Scott Braunstein	director	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Andrew Guggenhime	director	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Jason O'byrne	officer: See Remarks	CARIBOU BIOCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710